Melanoma News and Research

Latest Melanoma News and Research

Prostate cancer immunotherapy vaccine hits clinical trials

Scientists at the Austrlia's, Queensland Institute of Medical Research (QIMR) are currently trialing an experimental "immunotherapy" treatment for men with advanced prostate cancer.

10 Jun 2004

Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma

Early testing of an experimental human monoclonal antibody showed a striking benefit in patients with advanced melanoma, say researchers at The University of Texas M. D. Anderson Cancer Center, who presented their findings at the annual meeting of the American Society of Clinical Oncology.

7 Jun 2004

Crucial discovery may help better diagnose and treat children with Hirschsprung disease

Researchers at Fox Chase Cancer Center have made a crucial discovery that may help physicians better diagnose and treat children with Hirschsprung disease, a debilitating and sometimes life-threatening ailment that causes bowel obstruction and involves an array of genetic changes.

5 Jun 2004

Drug Tarceva improves survival chance for patients with advanced lung cancer

Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).

5 Jun 2004

Cancer rates falling in the US

The nation's leading cancer organizations report that Americans' risk of getting and dying from cancer continues to decline and survival rates for many cancers continue to improve.

3 Jun 2004

Avastin study shows significant improvement in patients with metastatic colorectal cancer

Genentech, Inc. and Roche have announced that the New England Journal of Medicine published the first Phase III study of an anti-angiogenesis cancer therapy, showing that the addition of Avastin™ (bevacizumab) to the IFL chemotherapy regimen (5-FU/Leucovorin/ CPT-11) significantly extended survival in patients with first-line (previously untreated) metastatic colorectal cancer.

2 Jun 2004

Innovative new cancer drug enters the first phase of clinical trials

An innovative drug with a new mechanism of action that may be effective against a range of cancers will enter the first phase of clinical trials, it was announced today (Monday) at Cancer Research UK's Senior Researchers Meeting.

24 May 2004

Phase 3 trial of Ceplene in acute myeloid leukemia meets primary trial endpoint

Maxim Pharmaceuticals has announced the results of an international Phase 3 clinical trial testing the combination of Ceplene (TM) plus interleukin-2 (IL-2) in 320 patients with acute myeloid leukemia (AML) in complete remission.

12 May 2004

Restrictions by health insurers and government to control expenses may hurt the malignant melanoma drug market

Decision Resources, Inc., a research and advisory firms focusing on pharmaceutical and health care issues, finds that restrictions by health insurers and government health authorities to control expenses may hurt the malignant melanoma drug market.

12 May 2004

World's first gene therapy trial aimed at preventing cancer

The concept seems straightforward. If, at its heart, cancer is a disease of genes, then giving patients new genes should disarm cancer. Such treatment would replace missing or faulty genes that keep cell growth in check, or would flush the body with "super genes" that could attack and destroy cancer.

5 May 2004

Australian company receives FDA orphan drug designation for product to treat malignant melanomas

Progen Industries Limited, an Australian anti-cancer drug development company, announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for their lead anti-angiogenesis product PI-88 for treatment of malignant melanoma.

3 May 2004

Misconceptions lead to late diagnosis of melanoma in African Americans

Susan C. Taylor, M.D., assistant clinical professor of dermatology, The College of Physicians and Surgeons, Columbia University in New York, addressed the alarming statistics that support the fact that prevention and detection messages about melanoma are not being heeded by African Americans.

3 May 2004

Teenagers ignore warnings on skin cancer

For most teens, getting a tan during spring break or in preparation for the prom is as common as these rites of passage themselves. Although teens hear dermatologists’ warnings that tanning is the most avoidable risk factor in the prevention of skin cancer, studies find they forgo this advice in favor of the bronzed look.

3 May 2004

UK, skin cancer specialists to check out moles

Macmillan skin cancer nurse, Denise Hancock, and colleagues from the Dermatology Department at Southampton University Hospitals Trust are inviting members of the public to 'check out their moles' at a Mole Watch Day in Marks and Spencer in West Quay on Wednesday 12 May, from 9am-5pm.

30 Apr 2004

Researchers find mucus plays key role in cancer

Investigators at the Dana-Farber/Harvard Cancer Center in Boston became intrigued with the thick, slimy stuff when they learned that breast, lung, colon, and other tumor cells make more than 50 times more of a certain type of it than normal cells.

29 Apr 2004

Skin cancer is now the UK's most common cancer in both men and women

Macmillan skin cancer nurse specialists will be promoting sun awareness and the dangers of skin cancer during Sun Awareness Week which runs from 10 to 16 May.

23 Apr 2004

New insights into how tumors neutralize CD8 T cells

Scientists have speculated that this may be because the immune response is not strong enough, or because it does not last long enough to have an effect. Hence the increasing efforts to develop cancer vaccines that induce, strengthen, and increase the duration of immunological attack against cancer cells.

16 Apr 2004

Cancer-specific protein offers new target for the development of melanoma vaccine

Scientists from the Cancer Vaccine Collaborative (CVC) have discovered that the cancer-specific protein, SSX-2, induces a spontaneous immunological reaction against cancer cells in melanoma patients, offering a new target for the development of a therapeutic melanoma vaccine. SSX-2 is the prototype of the SSX family, and is part of a larger group of proteins known as cancer/testis (CT) antigens.

16 Apr 2004

FDA approval for skin cancer cream

3M has received an "approvable" letter from the U.S. Food and Drug Administration (FDA) in response to its supplemental new drug application on Aldara (imiquimod) Cream, 5% for the treatment of superficial basal cell carcinoma (sBCC), a common form of non-melanoma skin cancer.

14 Apr 2004

FDA approves advanced malignant melanoma drug

Maxim Pharmaceuticals today announced that its treatment protocol to provide its investigational drug Ceplene(TM), in combination with interleukin-2 (IL-2), for the treatment of patients with advanced malignant melanoma, has been approved by the U.S. Food and Drug Administration (FDA).

14 Apr 2004